Show simple item record

Patients With Genetic Heart Disease and COVID-19: A Cardiac Society of Australia and New Zealand (CSANZ) Consensus Statement

Export
FieldValueLanguage
dc.contributor.authorGray, B.en
dc.contributor.authorSemsarian, C.en
dc.contributor.authorFatkin, D.en
dc.contributor.authorIngles, J.en
dc.contributor.authorAtherton, J.J.en
dc.contributor.authorDavis, A.M.en
dc.contributor.authorSanders, P.en
dc.contributor.authorPachter, N.en
dc.contributor.authorSkinner, J.R.en
dc.contributor.authorStiles, M.K.en
dc.contributor.authorCSANZ Cardiovascular Genetic Diseases Councilen
dc.date.accessioned2020-11-17
dc.date.available2020-11-17
dc.date.issued2020en
dc.identifier.urihttps://hdl.handle.net/2123/23852
dc.description.abstractIn the context of the current global COVID-19 pandemic, this Consensus Statement provides current recommendations for patients with, or at risk of developing, genetic heart disease, and for their health care management and service provision in Australia and New Zealand. Apart from general recommendations, there are specific recommendations for the following conditions: cardiomyopathy, Brugada syndrome (including in children), long QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT). Other recommendations are relevant to patient self-care and primary health care.en
dc.language.isoenen
dc.rightsOther
dc.subjectCOVID-19en
dc.subjectCoronavirusen
dc.titlePatients With Genetic Heart Disease and COVID-19: A Cardiac Society of Australia and New Zealand (CSANZ) Consensus Statementen
dc.typeArticleen
dc.identifier.doi10.1016/j.hlc.2020.04.006
usyd.facultyFaculty of Medicine and Health, Sydney Medical Schoolen


Show simple item record

Associated file/s

There are no files associated with this item.

Associated collections

Show simple item record

Version history

There are no previous versions of the item available.